home / stock / lgvn / lgvn news


LGVN News and Press, Longeveron Inc. From 06/17/24

Stock Information

Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com

Menu

LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...

LGVN - Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer’...

LGVN - Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, tod...

LGVN - US Companies Moving the Markets, Evening edition
Fri, Jun 14, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...

LGVN - US Companies Moving the Markets, Morning edition
Fri, Jun 14, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...

LGVN - Should New Investors Buy Penny Stocks?

2024-06-14 06:02:00 ET Why New Investors Should Look Into Investing in Penny Stocks Penny stocks offer an intriguing entry point for new investors looking to tap into the stock market without a substantial initial investment. These stocks, typically priced under $5, allow individuals to...

LGVN - US Companies Moving the Markets, Evening edition
Thu, Jun 13, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 3.5% to $129.61 on volume of 255,610,868 shares Longeveron Inc. (LGVN) rose 48.6% to $2.69 on volume of 190,987,878 shares PROSHARES TRUST (SQQQ) fell 1.6% to $8.54 on volume of 116,711,722 shares Tesl...

LGVN - Longeveron Inc. (NASDAQ: LGVN) Near Top of Volume Charts in Thursday Trading

Longeveron Inc. (NASDAQ: LGVN) is one today's most active stocks by volume. So far today, approximately 141.12M shares of Longeveron Inc. have been exchanged, as compared to an average 30-day volume of 3.5M shares. Longeveron Inc., a clinical stage biotechnology company, develops cellular ther...

LGVN - US Companies Moving the Markets, Morning edition
Thu, Jun 13, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Sharps Technology Inc. (STSS) rose 39.8% to $0.4185 on volume of 56,031,365 shares Nuburu Inc. (BURU) fell 36.1% to $0.0933 on volume of 49,471,677 shares BioRestorative Therapies Inc (BRTX) rose 66.7% to $2.25 on volume of 46,968,012...

LGVN - US Companies Moving the Markets, Evening edition
Wed, Jun 12, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 3.5% to $125.2 on volume of 291,129,456 shares Apple Inc. (AAPL) rose 2.9% to $213.07 on volume of 194,159,376 shares PROSHARES TRUST (SQQQ) fell 3.9% to $8.68 on volume of 178,616,604 shares Golden He...

LGVN - Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B(TM) as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

With current HLHS treatment, only 50-60% of infants survive to adolescence In ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical c...

Previous 10 Next 10